JAK inhibitor 'looks promising for ankylosing spondylitis'
A study shows improvements in patient pain and function with few serious adverse events, researchers say
AusDoc brings you the latest news from the American College of Rheumatology virtual congress 2020.
The Janus kinase inhibitor tofacitinib is shaping up as a potentially useful therapy for treatment of ankylosing spondylitis, according to results from a phase 3 randomised controlled trial.
The Pfizer-sponsored study of 269 adult patients with active ankylosing spondylitis found significant superiority of tofacitinib over placebo, although at the expense of more adverse events,